Acclaro Medical, the company behind the FDA-cleared UltraClear™ Laser-Coring™ system, has raised $23 million in Series B funding to further commercialize its first-of-its-kind aesthetic technology and expand global access to non-invasive skin rejuvenation solutions.

Led by CEO Helen F., the round was backed by healthcare-focused investors Accelmed and 3E Bioventures Capital, among others. The funding will support commercial scaling in the U.S., product development, provider training, and international regulatory approvals.

The company’s flagship product, UltraClear™, uses a patented Laser-Coring™ technique designed to stimulate collagen regeneration deep within the dermis - without cutting, burning, or prolonged downtime. For patients with deep wrinkles, scars, or aging skin, it offers dramatic improvement without the invasiveness of surgery or ablative lasers.

---

What Makes UltraClear™ Different?

Traditional resurfacing lasers work by ablating the skin’s surface or applying heat to stimulate collagen production. These approaches often require lengthy downtime, carry risks of pigmentation or scarring, and may be ineffective for deeper issues like atrophic scars and deep rhytids.

Acclaro’s Laser-Coring™ approach, however, physically removes micro-columns of aged tissue below the skin surface - stimulating wound healing and new tissue formation while leaving the outer epidermis largely intact. This allows for:

• Reduced pain and downtime compared to ablative lasers
  
• High efficacy for deep wrinkles, acne scars, and stretch marks
  
• Safe use across diverse skin tones (including Fitzpatrick types IV–VI)
  
• Minimally invasive procedures performed in-office
  

It’s a category-defining approach that combines the effectiveness of surgery with the convenience of non-invasive lasers.

---

Why This Raise Is So Timely

The global demand for non-surgical cosmetic treatments has exploded, especially among patients seeking results without the recovery associated with plastic surgery or aggressive resurfacing.

• The global aesthetic laser market is projected to reach $3.4 billion by 2028, growing at a CAGR of 12.5% (Fortune Business Insights).
  
• Minimally invasive aesthetic procedures have outpaced surgical ones, comprising over 80% of all aesthetic treatments globally (American Society of Plastic Surgeons).
  
• A growing population of Millennials and Gen X patients - many of whom seek natural-looking results and preventative aging solutions - are fueling growth in skin-focused devices.
  
• Providers are actively looking for differentiating technologies that offer high ROI per square foot, minimal consumables, and strong patient retention.

Acclaro sits at the intersection of all of these forces, offering a platform that delivers clinical results and economic efficiency.

But what makes their strategy so potent isn’t just the product. It’s the precision of the positioning. Acclaro didn’t try to fight for share in the crowded fractional laser arena - they redefined the conversation entirely with Laser-Coring™. This wasn’t a feature upgrade; it was a category claim.

And this is where founders should pay close attention.

In highly regulated, clinical, or high-barrier markets, category creation isn’t just marketing - it’s a risk mitigation strategy. If you play by incumbent rules, you’re judged by incumbent benchmarks: speed, wattage, price per shot, or patient downtime. But when you introduce a new clinical mechanism - like coring instead of ablating - you reset what matters. You dictate the metric.

More importantly, you expand the budget.

Rather than competing for attention in the “aesthetic laser” line item, Acclaro opens the door to dermatologic surgery budgets, regenerative therapy programs, and hybrid procedure bundles. Founders building in complex markets can use this lesson to unlock new revenue architecture: create a new outcome, not just a new tool.

That’s how you win - not by incrementally improving what exists, but by shifting what’s expected. Acclaro understood that the greatest moat is not just IP - it’s mindshare. Laser-Coring™ isn’t just a technology. It’s a new mental model for what’s possible in skin rejuvenation.

---

But here’s where their strategy gets truly insightful - and where founders in any medical or hardware startup should take note.

Instead of trying to “beat lasers at their own game,” Acclaro reframed the category entirely. They didn’t build a better fractional laser - they invented a new class: Laser-Coring™.

And this is the value drop.

What Acclaro teaches is that dominant startups don’t iterate within a crowded feature set - they carve out a space where they’re the only option. If your product competes on incrementals (faster, cheaper, more ergonomic), you’re in a race to the bottom. But if you change the underlying physics - literally or metaphorically - you reset the category.

This is true for B2B SaaS, for consumer hardware, for biotech. You don’t have to out-market the incumbents if you can change what people are looking for entirely.

Acclaro didn’t position themselves as another skin resurfacing tool. They positioned themselves as the non-surgical answer to problems previously reserved for scalpels - a far more defensible, ownable narrative.

---

What the Market Says

There’s strong validation for Acclaro’s approach from both providers and patients:

• UltraClear has been adopted by a growing number of top dermatology and medspa clinics in the U.S. since its FDA clearance
  
• Physicians report greater patient satisfaction due to minimal downtime and visible results within days
  
• The device requires minimal consumables, making it high-margin for practices
  
• UltraClear is being evaluated for future indications beyond aesthetics, including scar remodeling, stretch marks, and post-surgical skin regeneration
  

Additionally, the company is exploring how AI-guided treatment protocols could be layered on top of its Laser-Coring™ hardware to further personalize care and optimize outcomes - a move that could differentiate Acclaro even further in a data-driven future.

---

Market Outlook: Aesthetic Medicine Is Booming - But Patients Want More Than Vanity

The aesthetic medicine industry is no longer just about luxury. It’s about accessibility, longevity, and performance-driven results - and that’s exactly where Acclaro Medical is positioned to lead.

• The global aesthetic laser market was valued at $1.8 billion in 2022, and is projected to reach $3.4 billion by 2028, growing at a CAGR of 12.5% (Fortune Business Insights, 2023).
  
• According to the American Society for Dermatologic Surgery, demand for minimally invasive skin rejuvenation procedures rose by over 70% between 2017 and 2022, with laser-based treatments seeing the sharpest increase.
  
• Millennials and Gen X patients now make up the largest demographic seeking aesthetic care - prioritizing natural-looking, preventative, and non-surgical options.
  
• A 2023 RealSelf consumer insights report found that 86% of aesthetic patients cite recovery time and side effects as key decision-making factors - making technologies like UltraClear™ Laser-Coring™ highly appealing.
  
• Additionally, practices are seeking efficiency: devices with low consumable costs and high patient throughput have a 43% higher likelihood of year-over-year ROI, according to a 2023 survey of aesthetic clinic operators by Medical Economics.
  

The regulatory momentum is also in Acclaro’s favor. New FDA guidance around “aesthetic health” as a wellness driver is opening the door for advanced treatment categories to be viewed not just as cosmetic - but as quality-of-life interventions.

As skin health becomes a legitimate aspect of preventive care, Acclaro’s ability to deliver clinically significant tissue remodeling with minimal invasiveness puts it in a category that serves both vanity and vitality - a rare overlap that signals enormous upside.

---

What’s Next for Acclaro Medical?

With $23M in Series B capital secured, Acclaro Medical is entering a new phase of growth with key initiatives on the roadmap:

• Expand U.S. sales team and regional training centers for providers
  
• Launch targeted consumer education campaigns around Laser-Coring™
  
• Seek regulatory approvals in Europe, Asia-Pacific, and LATAM
  
• Invest in R&D for next-gen energy platforms and software layering
  
• Deepen clinical partnerships to expand indication use and peer-reviewed evidence
  

As the aesthetics market matures, patients and providers alike are demanding more than just flashy tech - they want real outcomes with minimal trade-offs. Acclaro Medical is poised to meet that demand with a category-shifting innovation and a clear go-to-market strategy that puts safety, science, and patient experience first.

For anyone watching the future of aesthetic medicine, Acclaro isn’t just raising money - they’re raising the bar.